Dupixent and Narrowband UVB for Atopic Dermatitis

Recruiting now · Phase 4

Conditions studied: Atopic Dermatitis

In brief

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Key facts

Study ID

NCT05285839

Run by

Psoriasis Treatment Center of Central New Jersey

People needed

40

Starts

2022-04-19

Expected to finish

2024-12-15

Last updated by the study team

2024-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adult ≥ 18 years of age;
• Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
• EASI score of 16 or greater,
• IGA score of 3 or greater
• BSA of 10% or greater,

You may not qualify if…

• Subjects with previous exposure to dupilumab.
• Known or suspected hypersensitivity to dupilumab or any of its excipients.
• History of photosensitivity.

Where it is running

• Eczema Treatment Center of New Jersey — East Windsor, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.